Analgesia for newborn infants during mechanical ventilation : a clinical and pharmacokinetic study by Saarenmaa, Elina
Hospital for Children and Adolescents,
and Department of Clinical Pharmacology
University of Helsinki, Finland
ANALGESIA FOR NEWBORN INFANTS DURING
MECHANICAL VENTILATION
- a clinical and pharmacokinetic study
by
Elina Saarenmaa
ACADEMIC DISSERTATION
To be publicly discussed by permission of the Medical Faculty
 of the University of Helsinki, in the Niilo Hallman
 Auditorium of the Hospital for Children and Adolescents,
on March 23rd, at 12 noon.
HELSINKI 2001
Supervised by
Docent Vineta Fellman, MD
Hospital for Children and Adolescents
University of Helsinki
Helsinki, Finland
Professor Pertti Neuvonen, MD
Department of Clinical Pharmacology
University of Helsinki
Helsinki, Finland
Reviewed by
Professor Mikko Hallman, MD
Department of Pediatrics
University of Oulu
Oulu, Finland
Docent Kalle Hoppu, MD
Poison Information Centre
Helsinki University Central Hospital
Helsinki, Finland
Official opponent
Professor Neil McIntosh, MD
Department of Child Life and Health
University of Edinburgh
Edinburgh, United Kingdom
ISBN 952-91-3245-X (nid.)
ISBN 951-45-9882-2 (PDF)
Helsinki 2001
Yliopistopaino
          To Ari,
Sara, Miro and Ilari
4CONTENTS
1 ABSTRACT ............................................................................................... 6
2 LIST OF ORIGINAL PUBLICATIONS ................................................... 8
3 ABBREVIATIONS ................................................................................... 9
4 INTRODUCTION ...................................................................................... 10
5 REVIEW OF THE LITERATURE ............................................................ 11
5.1 Pain in newborn infants ................................................................. 11
Perception of pain ..................................................................... 11
Physiological changes associated with pain .............................12
Behavioral changes associated with pain ................................. 13
5.2 Painful situations in the postnatal period ...................................... 14
5.3 Pain assessment ............................................................................. 15
Theoretical basis ...................................................................... 15
Unidimensional instruments ..................................................... 16
Multidimensional instruments .................................................. 17
5.4 Developmental aspects of pharmacokinetics in newborn infants . 19
Distribution and protein binding .............................................. 19
Metabolism ............................................................................... 20
Excretion ................................................................................... 21
5.5 Pain management .......................................................................... 22
Decreasing noxious stimuli .......................................................... 22
Environmental and behavioral interventions ........................... 22
Pharmacologic interventions ................................................... 23
Morphine ................................................................. 24
Fentanyl ................................................................... 25
Alfentanil ................................................................. 27
Ketamine ..................................................................28
6 AIMS OF THE STUDY ............................................................................. 30
7 SUBJECTS AND METHODS ................................................................... 31
7.1 Patients .......................................................................................... 31
7.2 Study design .................................................................................. 33
Fentanyl or morphine for ventilated newborn infants (I, II, III) . 33
Alfentanil for procedural pain relief in neonates (IV) ................. 34
Ketamine for procedural pain relief in neonates (V) ................... 34
7.3 Blood sampling ............................................................................. 35
57.4 Outcome measures ........................................................................ 35
Behavioral pain assessment ...................................................... 35
Physiological parameters ..........................................................36
Hormonal assays .......................................................................36
Determination of drug concentrations ...................................... 36
Pharmacokinetic calculations .................................................. 37
7.5 Adverse events .............................................................................. 37
7.6 Statistical analysis ......................................................................... 38
7.7 Ethical considerations ................................................................... 39
8 RESULTS ................................................................................................... 40
8.1 Comparison of analgesic effects of fentanyl and morphine (I) ........ 40
8.2 Serum concentrations, clearance, and effects of fentanyl (II) .......... 42
8.3 Serum concentrations, clearance, and effects of morphine (III) ...... 44
8.4 Alfentanil as procedural pain relief (IV) .......................................... 47
8.5 Ketamine as procedural pain relief (V) ............................................ 48
9 DISCUSSION ............................................................................................ 49
9.1 Methodological considerations ..................................................... 49
9.2 Analgesia for persistent pain ......................................................... 51
Comparison of fentanyl and morphine pharmacodynamics (I). 51
Pharmacokinetic studies (II, III) ............................................... 53
9.3 Procedural pain management (IV, V) ........................................... 56
10 CONCLUSIONS ........................................................................................ 58
11 ACKNOWLEDGMENTS .......................................................................... 59
12 REFERENCES ........................................................................................... 61
ABSTRACT

6
1  ABSTRACT
The perception of pain in newborn infants has been underestimated until recently,
since the infant´s ability to verbalize pain is limited. Newborn infants undergoing
intensive care are exposed to repeated painful procedures as well as persistent
pain. Thus, they are in need of pain relief. The objectives of this study were to
design clinically applicable, safe, and effective analgesia for persistent pain and
distress in the immediate postnatal period as well as short-acting pain relief for
procedures.
The pharmacodynamics and pharmacokinetics of fentanyl and morphine were
studied in newborn infants on mechanical ventilation. In a randomized double-
blind trial, 163 infants were allocated to receive a continuous infusion of fentanyl
(10.5 µg/kg over a 1-hour period followed by 1.5 µg/kg/h) or morphine (140
µg/kg over a 1-hour period followed by 20 µg/kg/h) for at least 24 hours. The
severity of pain was assessed using a behavioral pain scale, physiological
parameters, and stress hormone concentrations. As side effects, decreased
gastrointestinal motility and urinary retention were assessed. Serum
concentrations of fentanyl or morphine and metabolites of morphine, morphine-
3-glucuronide (M3G) and morphine-6-glucuronide (M6G), were assessed in
subgroups of 38 fentanyl-treated and 31 morphine-treated infants. Usefulness of
alfentanil and ketamine as procedural pain relief was studied in two separate
randomized, double-blind, crossover trials. Two different doses of alfentanil (10
and 20 µg/kg) and placebo were infused in a random order 2 minutes before three
separate endotracheal suctions to 10 infants, and three different doses of
ketamine (0.5, 1, and 2 mg/kg) and placebo were infused 5 minutes before four
separate endotracheal suctions to 16 infants, respectively. Behavioral pain score,
physiological parameters, and stress hormone concentrations were measured.
Fentanyl and morphine infusions provided effective analgesia, as judged by the
pain scale. Plasma catecholamine concentrations decreased in both treatment
groups at 24 hours, but ß-endorphin decreased only in the fentanyl group.
Decreased gastrointestinal motility occurred significantly less frequently in the
fentanyl-treated (23%) than in the morphine-treated (47%, p<0.01) infants. Mean
serum fentanyl steady-state concentration of 2.5 ± 1.0 ng/ml and mean serum
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morphine steady-state concentration of 167 ± 77 ng/ml were achieved between
24 and 48 hours of constant infusion. The fentanyl steady-state concentration
correlated with the concomitant pain score value (r= -0.57, p<0.01). Mean
clearances of fentanyl (11.5 ± 4.0 ml/min/kg) and morphine (2.4 ± 1.1
ml/min/kg) correlated with gestational age (p<0.01) as well as birthweight
(p<0.01). Significantly higher morphine concentrations were measured in the
infants with decreased gastrointestinal motility (187 ± 82 ng/ml) than in those
with normal motility (128 ± 51 ng/ml, p<0.05). In both alfentanil and ketamine
trials, heart rate and arterial blood pressure increased in association with
endotracheal suction after placebo. Attenuation of the pain score change in
response to endotracheal suction was noticed with 20 µg/kg alfentanil and 1
mg/kg ketamine. Rigidity appeared in five of eight infants receiving 20 µg/kg
alfentanil.
In conclusion, when comparing fentanyl and morphine infusions for persistent
pain, both proved to be effective. The lower incidence of decreased
gastrointestinal motility in the fentanyl group may, however, render it superior to
morphine, especially for premature infants with a high risk for decreased
gastrointestinal motility. The metabolism of fentanyl and morphine during the
postnatal period showed a large interindividual variability. However, since the
clearances of both fentanyl and morphine were correlated with gestational age
and birthweight, the degree of immaturity should be taken into account when
administering these drugs to newborn infants. As procedural pain relief, while
using endotracheal suction as a pain stimulus, only alfentanil at a dose of 20
µg/kg appeared effective. Nonetheless, because it caused a high rate of rigidity, it
should only be used in conjunction with a muscle relaxant. Ketamine used alone
appeared to be a poor pretreatment for endotracheal suction in the postnatal
period.
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3  ABBREVIATIONS
CHEOPS Children’s Hospital of Eastern Ontario Pain Scale
CI confidence interval
CRIES Crying, Requires oxygen to maintain saturation greater than 95%,
Increased vital signs, Expression, Sleeplessness
CV coefficient of variation
CYP cytochrome P-450 enzyme
DSVNI Distress Scale for Ventilated Newborn Infants
HPLC high-performance liquid chromatography
IBCS Infant Body Coding System
IQR interquartile range
LIDS Liverpool Infant Distress Scale
M3G morphine-3-glucuronide
M6G morphine-6-glucuronide
NFCS Neonatal Facial Coding System
NICU neonatal intensive care unit
NIPS Neonatal Infant Pain Scale
NMDA N-methyl-D-aspartate
NSAID nonsteroidal anti-inflammatory drug
PAT Pain Assessment Tool
PID pain intensity difference
PIPP Premature Infant Pain Profile
SD standard deviation 
SUN Scale for Use in Newborns
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4  INTRODUCTION
During the last two decades, while immense development has occured in neonatal
intensive care, few reports have been published suggesting that neonates feel pain,
suffer from pain, and should be treated for pain (Levine and Gordon 1982,
Williamson and Williamson 1983). The initiation of pain research in the newborn
infant can be ascribed to the first randomized controlled trial by Anand et al.
(1985), who demonstrated accentuated hormonal responses in neonates undergoing
surgery without anesthesia. Debate arose in the media as to whether these trials
were unethical or inhuman, although the control group received the standard
clinical practice at that time, which was no pain relief (Anand et al. 1987).
It has been conclusively documented that the newborn, including the premature
infant, is capable of perceiving pain (Anand and Hickey 1987, Truog and Anand
1989). Low birthweight infants show hormonal and metabolic responses to painful
stimuli, and these responses can be attenuated by efficient analgesia (Anand and
Hickey 1987). Use of analgesics during surgery and postoperative care reduces
complications (Anand and Hickey 1992), while the deleterious and long-lasting
effects on behavior due to untreated pain are evident from recent publications
(Anand and Hickey 1987, Lloyd-Thomas and Fitzgerald 1996, Taddio et al. 1997).
However, the most important issue is whether the benefits of treatment outweigh
the side effects and potential hazards.
The rationale for the present study was the clinical need for effective and safe
continuous analgesia for infants exposed to repeated procedures and nociceptive
stimuli while treated with mechanical ventilation during intensive care. Further, a
clinical need exists for a short-acting drug with little respiratory depressing side
effects, which could be used as an analgesic for minor painful procedures.
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5  REVIEW OF THE LITERATURE
5.1  Pain in newborn infants
Pain is defined as “an unpleasant sensory and emotional experience associated with
actual or potential tissue damage or described in terms of such damage” by the
International Association for the Study of Pain (Merskey et al. 1979). According to
this definition, pain is always a subjective phenomenon modified by context,
biological variation, and a variety of psychological factors and experiences related
to injury in early life.
The requirement for subjective reporting conceptualizes pain as an adult
experience, excluding preverbal or nonverbal individuals. An alternative system
based on empirical evidence purports that physiological and behavioral responses
are valid indicators of pain. This perspective suggests that pain is an inherent
quality of life that appears early in ontogeny to serve as a signaling system for
tissue damage (Anand and Craig 1996). This reconceptualization of pain is also
applicable to fetal life and infancy.
Nociception describes neurobehavioral and metabolic effects of a noxious stimulus
independent of higher consciousness, memory, emotional effects, or suffering.
Stress applies to adaptive responses generated by external stimuli or internal cues.
Distress is the suffering resulting from the emotional effects of excessive stress.
Perception of pain
Research of pain in children accelerated in the 1980’s, and since then, it has been
scientifically proven that newborn infants, even ones born prematurely, are capable
of feeling pain (Anand and Hickey 1987, Truog and Anand 1989). Providing
effective analgesia during neonatal intensive care has been neglected until recently,
however, because of uncertainty about its necessity and fear of possible side effects.
This has been the case despite studies indicating that in premature infants afferent
pain pathways and cortical centers are developed, and thus, the physiological
requirements for feeling pain are present (Anand and Carr 1989).
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Cutaneous pain receptors are present over the entire body at 20 weeks
postconception (Valman and Pearson 1980). Myelinization of nerve tracts in the
spinal cord, brain stem, and thalamus is complete by 30 weeks of gestation, and
thalamocortical pain fibers in the posterior limb of the internal capsule and corona
radiata by 37 weeks of gestation (Gilles et al. 1983). In addition, pain threshold is
lower in neonates than in adults because of immature organization of connections
within the dorsal horn of the spinal cord and not yet fully developed inhibiting
processes (Fitzgerald and Anand 1993, Chiswick 2000). This pain threshold is
lower still in preterm infants and is presumed to increase with postnatal age and
after painful procedures (Johnston and Stevens 1996). However, in contrast to these
assumptions, a recent study showed that thresholds remain low after injury even in
term infants (Andrews and Fitzgerald 1999). This suggests that exposure to
multiple procedures in the neonatal intensive care unit (NICU) increases pain
awareness (Chiswick 2000). Thus, newborns have all the anatomical and functional
components required for perception of pain and seem to experience more pain than
older children and adults.
Physiological changes associated with pain
Pain and stress in newborn infants causes changes in cardiovascular variables,
regional blood flow, respiratory patterns, oxygenation, and temperature. Increases
in heart rate and blood pressure have been noted in preterm and term infants with
heel lancing (Field and Goldson 1984, Owens and Todt 1984, Johnston and Strada
1986, McIntosh et al. 1993) and circumcision (Holve et al. 1983, Williamson and
Williamson 1983). Increased palmar sweating (Harpin and Rutter 1983) and
electrical conductance of the skin (Gladman and Chiswick 1990) have also been
observed in association with heel-prick in neonates.
Hormonal responses associated with painful stimuli include release of
catecholamines (Anand et al. 1985, Anand et al. 1990, Quinn et al. 1993), beta-
endorphin (Anand et al. 1985, Ionides et al. 1994), growth hormone, glucagon
(Anand et al. 1985), cortisol (Obara et al. 1984), aldosterone, and renin (Fiselier et
al. 1983), and suppression of insulin secretion (Anand et al. 1985). These responses
stimulate metabolic changes resulting in the breakdown of carbohydrate, protein,
and fat stores, leading to hyperglycemia, marked increases in levels of blood
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lactate, pyruvate, total ketone bodies, and fatty acids and enhanced nitrogen
excretion (Elphick and Wilkinson 1981, Anand et al. 1985). These changes have
been measured primarily in neonates undergoing surgery (Anand et al. 1987, Anand
et al. 1988, Anand et al. 1990, Anand and Hickey 1992) and circumcision without
anesthesia (Talbert et al. 1976, Masciello 1990) but also in relation to minor
procedures (Greisen et al. 1985, Lagercrantz et al. 1986) and postnatal mechanical
ventilation (Greenough et al. 1987, Greenough et al. 1990).
Other physiological changes in response to pain- and injury- associated stress
include alteration of the immunological system (Ward-Platt et al. 1989) and effects
on coagulation and hemostasis (Anand and Hickey 1992).
Behavioral changes associated with pain
Motor movements, facial expression, crying, and changes in behavior patterns, such
as sleep-wake cycles, are associated with pain experience. Noxious stimulus to the
sole of the foot stimulates pain receptors, which pass the impulse via C- and A-delta
fibers to the dorsal horn of the spinal cord, and causes the reflex withdrawal of the
limb known as the cutaneous flexion reflex. This reflex is obvious and measurable
in preterm infants born at 26 weeks of gestation (Andrews and Fitzgerald 1994).
Infants respond to pain caused by pinprick with diffuse body movements or reflex
withdrawal of the limb in association with grimacing, crying, or both (McGrath
1987).
Distinct facial expressions associated with pain in infants have been validated and
classified (Johnston et al. 1993). These expressions include brows lowered and
furrowed, eyes squeezed shut, deepening of the nasolabial furrow, open lips, mouth
stretched vertically and horizontally, and a taut, cupped tongue.
The primary method of communication in newborns, that of crying, is also caused
by stimuli other than pain. Crying due to pain can be distinguished by
spectrographic analysis or by subjective evaluation by trained observers from cries
caused by hunger and fear (Levine and Gordon 1982, Wasz-Höckert et al. 1985,
Zeskind et al. 1985, Zeskind and Barr 1997). The spectrographic properties of pain
cry of healthy full-term neonates differs from those of preterm or sick neonates
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(Wasz-Höckert et al. 1971, Michelsson et al. 1977, Michelsson et al. 1983, Wasz-
Höckert et al. 1985).
Alterations in sleep-wake cycles, increased wakefulness, and irritability have been
found in neonates after heel-stick procedure (Field and Goldson 1984). A controlled
study showed that an intervention designed to reduce the amount of sensory output
and stressful stimuli during intensive care of preterm neonates was associated with
improved clinical and developmental outcomes (Als et al. 1986).
5.2  Painful situations in the postnatal period
Newborn infants undergoing intensive care are repeatedly exposed to events
considered noxious by older children and adults. Environmental stress factors
include bright light, loud noise, and frequent handling during nursing procedures.
The need for continuous monitoring and mechanical ventilation may also cause
pain and stress. Many procedures commonly performed in the NICU result in acute,
immediate pain lasting for seconds or minutes. Tissue-damaging procedures
include heel lance, insertion of intravenous and arterial lines, suprapubic aspiration,
chest drain insertion, and lumbar puncture, among others. Intubation, endotracheal
suctioning, insertion of nasogastric tube, and handling for radiograph are
considered nontissue-damaging procedures.
In one study of 54 infants consecutively admitted to NICU, over 3000 procedures
were recorded (Barker and Rutter 1995). In another study of 124 infants born at 27
to 31 weeks of gestation, an average of 134 painful procedures per infant were
performed during the first two weeks of life (Stevens et al. 1999).
Surgery and subsequent postoperative course lead to subacute, longer lasting (hours
or days) pain. Acute painful stimulus primarily excites sensory receptors and
neurons (Pasternak 1988), whereas with subacute pain there is often an
inflammatory cytochemical or paracrine basis initiating or continuing the
sensorineural phenomenon (Fitzgerald 1995). Chronic persistent pain, defined as
lasting more than 3 months, is thus not a perfectly applicable term in the neonatal
period (Merskey 1986). However, the feature of inflammatory pain associated with
skin lesions, including massive edema and trauma, and certain neonatal illnesses,
such as necrotizing enterocolitis, meningitis, sepsis, and intracranial hemorrhages,
may more closely resemble severe chronic pain than acute or subacute pain.
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5.3  Pain assessment
Theoretical basis
Management of pain is based on pain assessment, which describes the
phenomenon and influencing factors, and evaluates the need and efficacy of
interventions. Quality and quantity of pain should be comparable within and
between infants using these assessment measures. Measurement is the
quantifiable aspect of assessment and applies to intensity of pain. The Children’s
Hospital of Eastern Ontario Pain Scale (CHEOPS) is a behavioral pain scale
developed to measure postoperative pain in 1- to 7-year-old children with good
reliability, validity, clinical utility, and feasibility (McGrath et al. 1985). It has also
been well validated for procedural pain. Different scaling procedures have been
developed to measure pain in the neonatal period (Craig et al. 1984, Grunau and
Craig 1987, Ambuel et al. 1992, Lawrence et al. 1993, Hodgkinson et al. 1994,
Pokela 1994, Krechel and Bildner 1995, Horgan and Choonara 1996, Sparshott
1996, Stevens et al. 1996, Blauer and Gerstmann 1998). The nominal or
categorical scale is a classification rather than a measurement (pain, no pain).
The ordinal scale reflects pain intensity, but the extent of increase or decrease is
not specified. With interval scales, the unit change in scale value represents a
constant change across the scale range, and calculation of average values is
possible.
Assessing pain and the efficacy of analgesia is a more comprehensive procedure
than pure measurement. It is generally difficult in the intensive care, because the
behavioral and physiological indicators of pain can be modified by extrinsic and
intrinsic factors. It is even more difficult in newborn infants, whose cognitive
response to pain is limited, and with whom self-report and instruments such as
visual analog scales cannot be used. In addition, measurement based on an
observer’s judgement is prone to bias due to the respondent’s own experience,
personality, and grasp of the situational context. Thus, a maximally objective
measure of newborn infants’ behavioral responses to pain, including visual
observation of facial expression and gross movement with or without
physiological and contextual indicators, has been used, and scoring systems have
been developed (Table 1).
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Gross motor activity is assessed by the Infant Body Coding System (IBCS, Craig et
al. 1984) with good reliability and validity. Motor activity of the hands, feet, arms,
legs, head, and torso is coded as either being present or absent.
The Behavioral Pain Score (Pokela 1994) consists of several types of behavioral
indicators including facial expressions, body movements, response to
handling/consolability, and rigidity of the limbs and body. It was developed from
CHEOPS (McGrath et al. 1985). The score of each indicator varies from 0 to 3,
with a total score ranging from 0 to 12.
The Liverpool Infant Distress Scale (LIDS, Horgan and Choonara 1996) was
developed to assess postoperative distress and pain in infants. It is reliable and
valid, but has not established clinical utility. Spontaneous movements, excitability,
flexion of fingers and toes, tone, facial expression, quantity and quality of crying,
and sleep are scored from 0 to 5.
Multidimensional instruments
Multidimensional instruments for infants are composed of behavioral,
physiological, and contextual indicators. The Neonatal Infant Pain Scale (NIPS,
Lawrence et al. 1993) includes five behavioral (facial expression, crying,
movement of arms and/or legs, state of arousal) and one physiological (breathing
pattern) indicator of pain. Indicators are scored from 0 to 1, except for crying (from
0 to 2), and the total score ranges from 0 to 7. The NIPS, developed for preterm and
term infants from CHEOPS (McGrath et al. 1985), is reliable and valid, but clinical
utility has not been established.
The Pain Assessment Tool (PAT, Hodgkinson et al. 1994) is designed to measure
postoperative pain in infants. Ten indicators (posture/tone, sleep pattern,
expression, color, crying, respiration, heart rate, oxygen saturation, blood pressure,
nurse’s perception of infant’s pain) are measured from 0 to 2, with total score
ranging from 0 to 20.
The CRIES (Crying, Requires 02 for saturation above 95%, Increased vital signs
(heart rate and blood pressure), Expression, Sleepless, Krechel and Bildner 1995),
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developed to measure postoperative pain in preterm and term infants, has
established validity and inter-rater reliability. Each of the five items is scored from
0 to 2, the total score ranging from 0 to 10.
The Premature Infant Pain Profile (PIPP, Stevens et al. 1996), composed of seven
behavioral, physiological, and contextual indicators, has established validity and
reliability (Ballantyne et al. 1999). It is designed to measure acute pain. The
indicators are gestational age, behavioral state, heart rate, oxygen saturation, brow
bulge, eye squeeze, and nasolabial furrow, each measured from 0 to 3, with the total
score ranging from 0 to 21. A total score of 6 or under indicates no pain; 12 or more
points indicate moderate to severe pain.
The Distress Scale for Ventilated Newborn Infants (DSVNI, Sparshott 1996) was
developed from several previous scoring systems to assess procedural pain in
ventilated infants. Four physiological indicators (heart rate, blood pressure, oxygen
saturation, and temperature differential, i.e. the gap between core and peripheral
temperatures) are measured as monitor readings. Three behavioral indicators are
scored (facial expressions and body movements from 0 to 3, and color from 0 to 2).
It has minimally established validity, but reliability and clinical utility have not
been established.
The Scale for Use in Newborns (SUN, Blauer and Gerstmann 1998), composed of
four physiological (CNS state, breathing, heart rate, mean blood pressure) and three
behavioral (movement, tone, facial expression) indicators, is valid and clinically
feasible. Each indicator is scored from 0 to 4 on a symmetric scale, with 2 being the
neutral level.
The Comfort Scale (Ambuel et al. 1992) is the only scale developed specificially to
measure distress in newborn infants in intensive care. It is a reliable and valid
measure composed of five behavioral (alertness, calmness/agitation, physical
movement, muscle tone, facial tension) and three physiological (respiratory
response, blood pressure, heart rate) indicators, each scored from 1 to 5, with the
total score ranging from 5 to 40.
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5.4  Developmental aspects of pharmacokinetics in newborn infants
Differences exist in drug absorption, distribution, protein binding, metabolism, and
excretion, not only between neonates and adults, but also between preterm
neonates, full-term neonates, infants, and children (Morselli 1989). Absorption is
not dealt with in this context since oral, intramuscular, rectal, subcutaneous, or
percutaneous routes of drug administration are rarely used in newborn infants in
intensive care environment. Administration of drug intravenously principally
assures nearly complete bioavailability, although there are some concerns. The drug
may be adsorbed into the infusion system or lost when the tubing is changed.
Moreover, a delay may occure before the drug reaches the systemic circulation,
because the infusion is given slowly, and this may lead to misinterpretation of the
infant’s response to the medication (Jacobson and Koren 1992). Despite these
concerns, intravenous infusion is the most reliable and feasible way of giving
analgesics to infants.
Distribution and protein binding
The amount of total body water and the relative volume of extracellular water
decrease rapidly during the first year of life (Friis-Hansen 1961). In preterm
neonates, water comprises up to 90% of total body weight; extracellular fluid
volume being 65%, intracellular fluid volume 25%, and fat less than 1% (Brans
1986). In full-term newborns, water comprises 70-75% of total body weight;
extracellular volume accounting for 40%, fat 15%, and skeletal muscle mass 20-
25%. By six months of age, total body water and extracellular water account for
60% and 30% of body weight, respectively, and the amount of fat increases to 25%
(Friis-Hansen 1971, Friis-Hansen 1983). In contrast, the brain and liver of the
neonate are larger in relation to body weight, and the myelin content of brain tissue
is lower than in adults (Morselli 1989).
The alterations in body composition and the qualitative and quantitative changes in
plasma proteins are accompanied by a reduction in plasma protein binding capacity
in the neonatal period. The concentration of albumin, which generally binds acidic
drugs, is lower in newborn infants, and especially in preterm infants, than in adults.
Further, fetal albumin has a low affinity for drugs, and endogenous compounds
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such as bilirubin compete for protein binding. Basic drugs bind to other proteins,
such as gamma-globulins, lipoproteins, and acid-alpha-1-glycoprotein, the latter of
which, as an acute-phase protein, may increase in response to surgery and stress
(Edwards et al. 1982).
Metabolism
Drugs are eliminated from the body by metabolic degradation in the liver and by
renal excretion. Hepatic clearance of a drug depends on liver blood flow and the
hepatic extraction ratio. Elimination of a drug with a high hepatic extraction ratio
(>0.7) is mainly dependent on hepatic blood flow, thus postnatal changes in this
flow are important with regard to pharmacokinetics. For drugs with a low (<0.3) to
intermediate (0.3-0.7) hepatic extraction ratio, hepatic clearance depends primarily
on hepatic enzyme activity and the degree of plasma protein binding (Rowland and
Tozer 1995, Scholz et al. 1996). Most drugs are lipophilic and must be transformed
into more water-soluble compounds before being excreted via the bile or kidneys.
Biotransformation occurs mostly in the liver and involves series of reactions
defined as phase I (oxidation, reduction, hydrolysis, and hydroxylation) and phase
II (conjugation with sulfate, acetate, glucuronic acid, glutathione, and glycine)
reactions.
Generally, phase I reactions lead to compounds with lower, equal, or higher
pharmacologic activity than the parent compound, and phase II reactions give rise
to inactive products. Concomitant or previous drug treatment or various
pathophysiological conditions may induce or inhibit these reactions. The
cytochrome P450 (CYP) superfamily, especially the CYP 3A subfamily, is the
most important hepatic enzyme system catalyzing phase I reactions. Glucuronosyl
transferases, sulfotransferases, and methyltransferases are the predominant phase II
enzymes. Traditionally, the developmental pattern of drug-metabolizing enzyme
activity is viewed as being very low in fetal organs, limited in the newborn infant,
rapidly increasing in the first year of life to children’s level, which may exceed
adult capacity, and finally declining to adult level at puberty. Recently, the
importance of genetic polymorphism and developmental differences in the activity
of drug-metabolizing enzymes during the perinatal and neonatal periods, through
infancy and childhood, and into adolescence have been recognized (deWildt et al.
1999a, deWildt et al. 1999b, Gow et al. 2001). Significant sulfotransferase activity
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is found as early as 14 weeks gestation in contrast to glucuronosyl transferase
activity, which is less than 10-30% of adult values in the neonatal period (Gow et
al. 2001).
Many drugs are metabolized mainly in the liver by the CYP3A subfamily, which
consists of at least three isoforms, CYP3A4, CYP3A5, and CYP3A7 (Nelson et al.
1996), located on chromosome 7 (Inoue et al. 1992). The most abundantly
expressed isoform, CYP3A4, accounts for approximately 30% to 40% of the total
CYP content in the human adult liver and small intestine (Watkins et al. 1987,
Kolars et al. 1994). CYP3A5, being 83% homologous to CYP3A4, is the main
CYP3A isoform in the kidney (Haehner et al. 1996). CYP3A7 is the prevailing
isoform detected in the human embryonic, fetal, and newborn liver. It is also
detected in the adult liver, but at a much lower level than CYP3A4 (Kitada et al.
1985, Yang et al. 1994, Tateishi et al. 1997). CYP3A7 activity is high during
embryonic and fetal life, decreasing rapidly during the first postnatal week. In
contrast, CYP3A4 activity is low before birth, but increases rapidly thereafter,
reaching 50% of adult levels between 6 and 12 months of age (Hakkola et al. 1994,
Lacroix et al. 1997). Profound changes occur in the activity of CYP3A isoforms
during all stages of development. These changes are clinically important when
treatment involves drugs that are substrates, inhibitors, or inducers of CYP3A.
Expression of CYP2D6 is low during the fetal period, but increases rapidly after
birth (Treluyer et al. 1991). Activity of CYP1A2 is minimal in fetal liver and seems
to reach adult levels by 120 days of postnatal age (Cazeneuve et al. 1994, Hakkola
et al. 1994). CYP2C9 activity in infants more than one week of age may exceed
adult enzyme activity (Leff et al. 1986). Ontogeny of CYP2C19 or of phase II
enzymes during the neonatal period has not been thoroughly studied. However,
important differences exist between children and adults, and the developmental
pattern of these enzymes varies (Leeder and Kearns 1997).
Excretion
Renal excretion, the principle route of drug excretion, depends on glomerular
filtration, tubular reabsorption, and tubular secretion. Renal function is limited at
birth because the kidney is anatomically and functionally immature (Strauss et al.
1981, Robillard et al. 1992). Gestational age and hemodynamic changes in the
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postnatal period are the main factors influencing development of renal function
(Aperia et al. 1981, Vanpee et al. 1993). At birth, glomerular filtration rate is
approximately 20 ml/min per 1.73 m2 in full-term infants and lower in preterm
infants, at only 10.2 to 13.0 ml/min per 1.73 m2 at 28 to 30 weeks of gestation
(Guignard and John 1986). A rapid increase occurs after birth because of increased
cardiac output. The increase is greater in full-term than in preterm infants (Arant
1978, Arant 1984, Schwartz et al. 1984). Adult values are reached and even
exceeded within one month after birth (Robillard et al. 1992). The renal tubular
secretory function is also low at birth because of the small size of tubules, the
limited number of tubular cells, and reduced blood flow (Guignard and Drukker
1999). The tubular function matures more slowly than glomerular filtration
(Besunder et al. 1988a, Besunder et al 1988b).
5.5  Pain management
Decreasing noxious stimuli
Environmental and behavioral pain management strategies include
nonpharmacologic interventions that should be considered the basis for all pain
management. Pain can be reduced indirectly by reducing the amount of noxious
stimuli to which infants are exposed, and directly by blocking nociceptive pathways
or by activating descending pain modulating systems. The most effective strategy
for decreasing pain in the neonatal intensive care unit is to strictly limit the
frequency and amount of painful caregiving and diagnostic procedures to those that
can be documented to positively affect outcome (Franck and Lawhon 2000). Blood
samples should be grouped to minimize the number of venipunctures per day,
noninvasive monitoring devices should be used when possible, and an indwelling
arterial line should be inserted to minimize the number of vein and artery punctures.
Environmental and behavioral interventions
Environmental stress can be decreased by reducing lighting levels, alternating day-
night conditions, and reducing noxious noise. Positioning infant to maintain flexed
position and providing a “nest” with blanket rolls stimulates proprioceptive,
thermal, and tactile sensory systems and facilitates self-regulation. The pain-
REVIEW OF THE LITERATURE

23
relieving effect of nonnutritive sucking has been studied (Field and Goldson 1984,
Miller and Anderson 1993, Stevens et al. 1999). The administration of sweet-tasting
substances (sucrose, glucose, or saccharin) prior to a minor procedure, e.g. blood
sampling, is effective in relieving pain (Blass and Hoffmeyer 1991, Rushforth and
Levene 1994, Bucher et al. 1995, Haouari et al. 1995, Abad et al. 1996, Ramenghi
et al. 1996, Johnston et al. 1997, Lindahl 1997, Skogsdal et al. 1997). The
effectiveness of analgesia depends on the concentration of the solution (Skogsdal et
al. 1997), and the most appropriate time to give the solution is two minutes prior to
sampling (Stevens et al. 1997). The analgesic effect seems to be transmitted
through the endogenous opioid system (Blass 1994, Lindahl 1997, Skogsdal et al.
1997, Stevens et al. 1997).
Pharmacologic interventions
Pharmacologic analgesia and sedation are usually appropriate for infants receiving
intensive care. Opioids, which also have a sedative effect, are the most commonly
used analgesics in the newborn period (Johnston et al. 1997, Anand et al. 1999).
Morphine and its synthetic derivative fentanyl are the preferred opioids. Pethidine
has a pharmacologic profile close to morphine, but its metabolite norpethidine is
neurotoxic. Alfentanil is a fentanyl derivative with rapid onset and brief duration of
action. Sufentanil is 5 to 10 times more potent than fentanyl, being the most potent
opioid in use. Its pharmacokinetic properties are intermediate to those of alfentanil
and fentanyl (Jacqz-Aigrain and Burtin 1996). Along with pharmacokinetic
properties, opioids vary in their side effects and potential for producing tolerance
and dependence.
Analgesic potency without a ceiling effect, maintenance of hemodynamic stability,
reversibility of side effects by antagonist drugs, and long-lasting clinical use in term
and preterm infants are clear advantages of opioids. Respiratory depression is a
common side effect. Neonates are believed to be more sensitive to opioids than
older children and adults; however, this claim has been questioned with regard to
morphine (Olkkola et al. 1988, Lynn et al. 1993, Nichols et al. 1993). In addition,
sensitivity to respiratory depression has even been reported to be reduced with
fentanyl and sufentanil (Greely et al. 1987, Gauntlett et al. 1988). Histamine release
may cause vascular dilatation, which may lead to hemodynamic instability and
bronchospasms, especially when the intravenous bolus is given rapidly. The
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histamine-releasing effect of morphine is greater than that of fentanyl (Rosow et al.
1982). On the other hand, fentanyl may stimulate muscle contractions causing chest
wall rigidity, particularly when given as a rapid intravenous bolus (Lindemann
1998). Other side effects of opioids are decreased gastrointestinal motility and
peristalsis, urinary retention, pruritus, and nausea and vomiting.
Tolerance and physical dependence develop with prolonged or repeated use of all
opioids. Signs of withdrawal including irritability, restlessness, insomnia, muscle
twitches and movement disorders (Norton 1988, Lane et al. 1991), arise mainly
from a pathological excitation of the central nervous system. Objective methods
have been developed to assess these withdrawal symptoms (Suresh and Anand
1998), which may occur as soon as 48 hours after initiation of morphine infusion,
but clinically significant withdrawal usually occurs after 5 days (Arnold et al.
1990). Gradual weaning diminishes the risk of withdrawal syndrome, which if
occurring, can be treated with pharmacologic and nonpharmacologic methods
(Suresh and Anand 1998).
Anesthetic agents, such as ketamine, have been used to provide analgesia and
sedation in NICU. Weak analgesics, such as salicylates and nonsteroidal anti-
inflammatory drugs (NSAIDs), are not recommended for use in neonates because
of side effects and the lack of sufficient scientifical studies or evidence-based
clinical guidelines or safety reports. Paracetamol is also extensively used for
treatment of mild pain in term neonates, but its efficacy and safety have not yet
been proven in preterm infants. Benzodiazepines are pure sedatives without
analgesic effect; midazolam is presently the most widely used sedative in neonates.
Chloral hydrate is also used to sedate newborn infants, but because of adverse
effects and a risk of hyperbilirubinemia, repeated doses should be avoided.
Morphine
Morphine is a µ receptor agonist and the most widely used opioid in neonatal
intensive care, the standard against which all other opioids are compared.
Pharmacokinetic studies of opioids show great differences between preterm and
term neonates, older infants (Table 2), children (Vandenberghe et al. 1983), and
adults (Stanski et al. 1978, Owen et al. 1983). The postnatal age of the infants
included in these studies varies greatly. The total plasma clearance and half-life
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vary with age, the clearance being slowest and the half-life longest in preterm
infants, with a considerable interindividual variation. Concurrent illness and surgery
affect the pharmacokinetics. Further, renal failure leads to accumulation of
morphine metabolites (Shelly et al. 1986, Faura et al. 1998), but liver failure has
only minor effects on morphine pharmacokinetics.
Morphine is metabolized in the liver via glucuronidation. The major metabolites are
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Sulfation is a
minor metabolic pathway. Glucuronidation is impaired in the neonatal period
(Choonara et al. 1989, Bhat et al. 1992, Chay et al. 1992, Choonara et al. 1992,
McRorie et al. 1992, Hartley et al. 1993a, Hartley et al. 1993b). M6G has a more
potent analgesic effect than morphine (Osborne et al. 1992, Barrett et al. 1996);
however, the clinical significance of M6G analgesia during morphine therapy is
unclear. Morphine metabolites are excreted in the urine and bile, but acutely ill
preterm infants also excrete unmetabolized morphine (Bhat et al. 1990, Bhat et al.
1992).
Plasma concentration of morphine required for analgesia or sedation seems to vary
greatly. Dahlström et al. (1979) reported concentrations of 65 ng/ml sufficient for
intra-operative analgesia, and Lynn et al. (1984) concentrations of 12 ng/ml for
postoperative analgesia in children. In infants, the mean analgesic concentration
postoperatively was 26 ng/ml as compared with 4 ng/ml in children aged 2-6 years
(Olkkola et al. 1988). Adequate sedation and analgesia was reported in 50% of
newborn infants receiving a mean morphine concentration of 125 ng/ml (Chay et al.
1992). In a recent study, however, the steady-state concentration (mean 210 ng/ml)
did not correlate with analgesia (Scott et al. 1999).
Fentanyl
The use of the synthetic opioid fentanyl for analgesia in newborn infants has
increased during the last decades. Fentanyl, as a highly lipophilic agent, is widely
distributed in tissues. It crosses the blood-brain barrier more rapidly than morphine,
having therefore a faster onset and a shorter duration of action.
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The pharmacokinetics of fentanyl in newborn infants has not been thoroughly
investigated (Table 2). The number of infants in each study is small and the
postnatal age varies greatly. Fentanyl has a high clearance rate in comparison with
morphine. It has a high extraction ratio (0.8 to 1.0) and is eliminated mainly by
hepatic metabolism. Liver blood flow and the activity of metabolizing enzyme CYP
3A4 affect the rate of elimination. Only small amounts of unmetabolized drug are
excreted in urine, and renal failure during cardiac surgery does not affect fentanyl
pharmacokinetics in children and adolescents (Koren et al. 1984). The elimination
half-life is significantly prolonged if hepatic blood flow is decreased or abdominal
pressure increased (Koehntop et al. 1986, Gauntlett et al. 1988).
Scarce data is available on the relationship of fentanyl concentration and its
analgesic effect in newborn infants. When using continuous infusion of fentanyl to
provide adequate sedation for NICU infants, those delivered at a gestational age of
less than 34 weeks were sedated with a mean plasma concentration of 1.7 ng/ml
and those delivered after 34 weeks with 2.1 ng/ml, respectively (Roth et al. 1991).
Alfentanil
Alfentanil, a structural analog of fentanyl, has been used as an analgesic for infants
receiving muscle relaxants (Marlow et al. 1990). It is less lipid-soluble, has a more
rapid onset, and a shorter duration of action than fentanyl (Jacqz-Aigrain and Burtin
1996). Plasma protein binding increases from 65% in preterm infants to 79% in
term infants (Wilson et al. 1997). The concentration of alfentanil declines rapidly
after intravenous administration. Pharmacokinetic properties vary between newborn
and older infants (Table 2), children (Meistelman et al. 1987, Roure et al. 1987),
and adults (Camu et al. 1982, Schuttler and Stoeckel 1982).
Alfentanil has intermediate extraction ratio (0.3 to 0.5), it is eliminated mainly by
hepatic metabolism, and only a small fraction is excreted unchanged in the urine.
Neither renal failure nor hepatic disease (Davis et al. 1989b) has an effect on the
pharmacokinetics of alfentanil.
No data appears to exist on the analgesic concentration of alfentanil in newborn
infants. Rautiainen (1991) estimated a steady-state concentration ranging from 50
to 220 ng/ml (mean 79 ng/ml) to be adequate for providing effective analgesia and
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sedation during cardiac catheterization in infants aged 1 to 17 months. In another
study with preterm infants, where a larger alfentanil dose (20 µg/kg initial bolus,
thereafter infusion of 3 µg/kg/h or 5 µg/kg/h) was used, median steady state
concentrations of 29 ng/ml and 55 ng/ml, respectively, were achieved (Marlow et
al. 1990). Intravenous doses of 10-20 µg/kg alfentanil provided analgesia and
diminished the physiological stress response caused by tracheal intubation or
treatment procedures such as tracheal suctions, blood samplings, and radiographic
examinations (Pokela 1993, Pokela and Koivisto 1994).
As side effects, central nervous system excitation and chest wall rigidity were noted
in 4 of 17 children receiving 50 µg/kg, 1 of 17 receiving 25 µg/kg, but none of 17
receiving 10 µg/kg alfentanil before the induction of intravenous anesthesia,
respectively (Lindgren et al. 1991). Severe rigidity was observed in 4 of 20
newborn infants in association with the administration of 9-15 µg/kg alfentanil
(Pokela et al. 1992).
Ketamine
Ketamine is an anesthetic agent chemically related to phencyclidine and
cyclohexamine, with analgesic properties at subanesthetic plasma concentrations
(Reich and Silvay 1989). It produces a blockade of N-methyl-D-aspartate (NMDA)
receptors and has been used for dissociative anesthesia in infants. The molecular
structure contains a chiral center at the C-2 carbon of the cyclohexanone ring,
permitting the existence of two optical isomers, s(+)ketamine and r(-)ketamine.
These two enantiomers differ in their anesthetic and analgesic potency, physical
side effects, and incidence of emergence reactions. The s(+)ketamine produced
more effective analgesia than racemate or r(-)ketamine, and this correlated with
degree of electroencephalogram changes and higher affinity for opiate receptors
(White et al. 1980, White et al. 1985). More psychic emergence reactions occurred
with r(-)ketamine treatment than after racemate or s(+)ketamine (White et al. 1980).
Previously, the commercially available racemic ketamine preparation contained
equal concentrations of both enantiomers, but s(+)ketamine alone has recently also
become available. The pharmacokinetic profiles for the individual isomers did not
differ from that of the racemic mixture (White et al. 1985).
In addition to effective analgesia, ketamine has been used to provide sedation and
amnesia for pediatric patients undergoing invasive procedures (Cotsen et al. 1997,
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Lowrie et al. 1998) and in the NICU in association with procedures (Tashiro et al.
1991, Betremieux et al. 1993). Advantages of ketamine include hemodynamic
stability and maintenance of respiratory function (Friesen and Henry 1986). Doses
of 2 mg/kg intravenously provided brief analgesia and sedation with low incidence
of hypoventilation (Cotsen et al. 1997). When doses of 5 mg/kg were given
intravenously to 10 critically ill preterm infants aged 1 to 10 days prior to
procedure, no changes in cerebral blood flow and transcutaneous gas pressures
were noted. Moreover, while arterial pressure decreased significantly, no changes
occurred in heart rate or cardiac output (Betremieux et al. 1993). Doses of 1 mg/kg
ketamine were used to sedate 25 preterm infants for cryotherapy at 3 months
postnatal age with no hemodynamic effects (Tashiro et al. 1991).
Adverse effects include emergence phenomena, increased intracranial pressure
(Friesen and Henry 1986), and hypertension. Concomitant midazolam use can
prevent emergence phenomena, described as a combination of bad dreams,
hallucinations, and delirium. However, emergence reactions have not been seen in
children younger than five years of age. Increased production of salivary and upper
respiratory secretions caused by ketamine can be relieved with atropine or
glycopyrolate.
Pharmacokinetic and pharmacodynamic data on ketamine during the neonatal
period is limited (Betremieux et al. 1993, Hartvig et al. 1993). In adults, analgesic
effect was observed with plasma concentrations of 150 ng/ml after intramuscular
administration and 40 ng/ml after oral administration, and awakening from
anesthesia occurred at plasma concentrations of 640 – 1120 ng/ml (Grant et al.
1981). In ten infants aged 1 week to 30 months, 1 mg/kg/h or 2 mg/kg/h ketamine
was used for postoperative analgesia and sedation (Hartvig et al. 1993). Children
were arousable at ketamine concentrations of 1000 – 1500 ng/ml. The mean plasma
clearance was 15.7 ml/min/kg and the elimination half-life was 3.1 hours. The rate
of conversion of two enantiomers is unknown in infants and the relationship of
isomers may differ from that of adults. The relationship between plasma
concentration and analgesic effect is also unclear.
Ketamine is metabolized in the liver by CYP enzymes to norketamine, an active
metabolite with anesthetic potency one third that of ketamine. Norketamine is
hydroxylated and excreted into the urine as conjugates.
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6  AIMS OF THE STUDY
The objectives of this study were :
To evaluate the efficacy, safety, and pharmacokinetics of opioid treatment for
persistent pain and distress in the early neonatal period (I, II, III).
To assess pain during brief standard procedures in the neonatal period and to find
an appropriate premedication (IV, V).
The specific objectives were:
1. To compare the efficacy of fentanyl and morphine in treating persistent pain (I).
2. To evaluate the efficacy of alfentanil in relieving acute pain (IV).
3. To evaluate the efficacy of ketamine in relieving acute pain (V).
4. To determine the pharmacokinetics of the drugs studied (II, III).
5. To assess adverse events of drugs used (I, IV, V).
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Ten newborn infants were enrolled in the alfentanil trial. The median gestational
age was 32 weeks (interquartile range (IQR) 29 to 36) and median birthweight 1440
g (IQR 1040 to 3160). The median age at enrollment was three days (IQR 2 to 6).
Sixteen newborn infants were enrolled in the ketamine trial. The median gestational
age was 31 weeks (IQR 29 to 33) and median birthweight 1160 g (IQR 1070 to
1900). The median age at enrollment was three days (IQR 2 to 5).
7.2  Study design
Fentanyl or morphine for ventilated newborn infants (I, II, III)
The randomization procedure of this double-blind study for allocation to either the
fentanyl or morphine group was carried out in five blocks using sealed and
numbered envelopes. The infants were stratified for birthweight into two groups,
less than 1500 g and greater than or equal to 1500 g.
The drug solution was prepared in 10% dextrose according to strict directions and
using the same drug concentration [morphine (MorphinR, Leiras, Turku, Finland)
40 µg/ml, and fentanyl (FentanylR, Janssen Pharmaceutica, Beerse, Belgium) 3
µg/ml] for all infants. The infusion was started as soon as possible after the
enrollment, at a rate of 3.5 ml/kg/h for one hour, to obtain a loading dose of 140
µg/kg morphine or 10.5 µg/kg fentanyl. The infusion provided 5.8 mg/kg/min
glucose. After 60 minutes, the infusion was decreased to a rate of 0.5 ml/kg/h,
corresponding to a dose of 20 µg/kg/h morphine, 1.5 µg/kg/h fentanyl, and 0.8
mg/kg/min glucose, respectively, and continuing for at least 24 hours.
Intensive care procedures and monitoring were performed according to standard
clinical practice. Mechanical ventilation was provided with Infant Star ventilators
(Infrasonics Inc, San Diego, CA, USA), primarily on the synchronized intermittent
mandatory ventilation mode. High-frequency oscillatory ventilation was used when
mean airway pressure exceeded 10 cmH20 or in case of air leak.
When the caretaking nurse evaluated the response to treatment procedures to be
painful on the basis of infant’s behavior, additional boluses of the investigational
drug solution were administered. A bolus of 0.5 ml/kg (morphine 20 µg/kg or
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fentanyl 1.5 µg/kg) could be given at most four times a day. A muscle relaxant was
used if the infant was struggling against the ventilator. Weaning from the opioid
infusion occurred gradually over 0.5 to 2 days depending on the duration of the
treatment.
Alfentanil for procedural pain relief in neonates (IV)
This double-blind, randomized, crossover trial contained three phases. Ten infants
received saline as placebo and two different doses of alfentanil (RapifenR, Janssen
Pharmaceutica, Beerse, Belgium), 10 µg/kg and 20 µg/kg, intravenously in random
order before three painful procedures spaced at least six hours apart. Seven infants
completed the entire protocol, one received two study doses, and two received only
one study dose each, because of removal of the arterial line.
Endotracheal suction, part of the routine treatment of the infants, was used as a
standardized painful procedure. The nurse responsible for drug preparation
performed the dilution of alfentanil from commercial vials according to randomized
instructions in sealed numbered envelopes. The diluted volume was the same (0.8
ml/kg) for all doses. Another nurse administered the drug slowly as a bolus over
two minutes, and after another two minutes, the endotracheal suction was started.
The infant was bag ventilated during the procedure, and if oxygen desaturation
occurred, the FiO2 was increased.
Ketamine for procedural pain relief in neonates (V)
This double-blind, randomized, crossover trial contained four phases. Each patient
received saline as placebo and three different doses of racemic ketamine (KetalarR,
Parke-Davis, Dublin, Ireland), 0.5 mg/kg, 1 mg/kg, and 2 mg/kg, intravenously in
random order before four painful procedures (endotracheal suction) spaced at least
twelve hours apart. One nurse performed the dilution of ketamine from commercial
vials and an equal volume (0.5 ml/kg) was infused for all doses. Another nurse
administered the drug slowly over two minutes. Five minutes after beginning of
injection, the endotracheal suction was started. The infant was bag ventilated during
the procedure, and if oxygen desaturation occurred, the FiO2 was increased.
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7.3  Blood sampling
Fentanyl-morphine trial (I, II, III) An arterial blood sample (1.5 ml blood in
ethylenediamine tetra-acetic acid vials containing 15 µl of 1% sodium-
metabisulphite) was obtained for determination of plasma adrenaline,
noradrenaline, and ß-endorphin concentrations upon entry to the study, and at 2 and
24  hours after  beginning  infusion.  The  samples  were  centrifuged  and stored at
-70°C until analyzed. Timed arterial blood samples (0.5 ml) for determination of
fentanyl or morphine, M3G, and M6G concentrations were collected into
Microtainer Brand Serum Separator Tubes (Becton Dickinson and Company,
Franklin Lakes, NJ, USA) at 2, 12, 24, 48, and 60 hours after beginning infusion.
Serum was separated within 60 minutes and stored at -70°C until analyzed.
Alfentanil trial (IV) Arterial blood was sampled (1.5 ml) before the solution was
administered and at 30 minutes after endotracheal suction for determination of
plasma adrenaline, noradrenaline, and ß-endorphin concentrations. A simultaneous
blood sample (0.5 ml) for determination of alfentanil concentration was obtained.
The samples were centrifuged and stored at -70°C until analyzed.
Ketamine trial (V) Arterial blood was sampled (1.0 ml) before the solution was
administered and at 10 minutes after endotracheal suction for determination of
plasma adrenaline and noradrenaline concentrations. A simultaneous blood sample
(0.5 ml) for determination of ketamine concentration was obtained. The samples
were centrifuged and stored at -70°C until analyzed.
7.4  Outcome measures
Behavioral pain assessment
Behavioral pain responses before, during, and after a routine tracheal suction were
assessed blindly by the caretaking nurse in the fentanyl-morphine trial and by the
researcher (ES) in alfentanil and ketamine trials. Scoring was not performed during
muscle relaxation in the fentanyl-morphine trial. Definition of the pain scale
adapted from the Neonatal Infant Pain Scale (NIPS) of the Children´s Hospital of
East Ontario Pain Scale (CHEOPS) is presented (IV, Table 1). Changes occurring
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in the five parameters during the procedure, as compared with before the procedure,
i.e. pain intensity difference (PID) was registered.
Physiological parameters
The heart rate, arterial blood pressure, and oxygen saturation were continuously
monitored (Hewlett Packard Neonatal Component Monitoring System, Andover,
MA, USA). Changes (from baseline) at certain time points (2, 12, 24, and 48 hours
after start of infusion) and in association with the standardized painful procedure,
endotracheal suction, were registered. Maximal changes within five minutes of the
administration of the investigational solution in the ketamine trial were also
registered.
Hormonal assays
Plasma noradrenaline and adrenaline concentrations were measured with high-
performance liquid chromatography (HPLC) using electrochemical detector (Esa
Coulochem Multi-Electrode, model 5100 A) (Eriksson and Persson 1982). The
detection limit was 10 pg/injection. Radioimmunoassay was used for determination
of ß-endorphin concentrations (Vuolteenaho et al. 1981). The detection limit was 2
pg/tube.
Determination of drug concentrations
Fentanyl-morphine trial (II) Serum fentanyl concentrations were determined by
radioimmunoassay (Janssen Research Foundation, Belgium) (Woestenborghs et al.
1987). The quantification limit was 1 ng/ml. The interassay coefficient of variation
(CV) was 7.2% (at mean 3.75 ng/ml; n=6).
Fentanyl-morphine trial (III) Serum morphine, M3G, and M6G concentrations
were determined using the reversed-phase ion-pair HPLC method (Svensson et al.
1982). The quantification limit for morphine and M6G was approximately 1 ng/ml,
and that for M3G approximately 3 ng/ml. The interassay CV was less than 5% for
morphine and M6G, and less than 3% for M3G.
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Alfentanil trial (IV) Serum alfentanil concentrations were determined with
radioimmunoassay, the detection limit of which was 1 ng/ml (Janssen Research
Foundation, Belgium).
Ketamine trial (V) Plasma ketamine (racemate) concentrations were determined by
HPLC using etidocaine as an internal standard (Adams et al. 1992). The limit of
quantification was 20 ng/ml, and the interassay CV was 6.5% at 196 ng/ml (n=5).
Pharmacokinetic calculations
Fentanyl and morphine steady states were considered achieved when the
concentrations in two consecutive samples were within 15% of each other, without
a consistent increase or decrease in the slope of the concentration-time curve during
the constant infusion. Total body clearance was calculated by dividing the infusion
rate with the concentration at steady state (Rowland and Tozer 1995).
7.5  Adverse events
Fentanyl-morphine trial (I,II,III) Gastrointestinal motility was assessed daily based
on passing of meconium and gastric retention defined as fluid reflux from the
nasogastric tube. Necrotizing enterocolitis was defined as stage II or III with Bell’s
staging system (Bell et al. 1978). Urinary retention was evaluated daily both
clinically and ultrasonographically. Retention was defined as loss of spontaneous
urination with enlarged bladder or reversible hydronephrosis. Attention was
focused on rigidity, which was repeatedly assessed during the infusion by the
caretaking nurse or neonatologist.
Alfentanil trial (IV) Special attention was paid to rigidity, which was graded in
terms of passive resistance to movement of the limbs relative to the pretreatment
level in four categories: muscle tone decreased or unchanged, slightly increased
muscle resistance, severe rigidity, or convulsive activity. Urinary retention was
evaluated clinically and at least once in each infant with ultrasound measurement.
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Ketamine trial (V) The caretaking nurse observed reactions to routine treatment
procedures. Attention was paid to possible unexpected behavioral features of the
infant while undisturbed, in an attempt to register occurrence of emergence
phenomena.
7.6  Statistical analysis
Data are presented as mean and standard deviation (± SD) or 95% confidence
interval (CI), or as median and interquartile range (IQR), when distribution of
values was skewed. Statistical significance was defined as p<0.05.
Clinically significant side effects, such as urinary retention and decreased
gastrointestinal motility, were observed in two thirds of cases when using morphine
in NICU prior to the trial, and this background prevalence was used when
calculating sample size in the fentanyl and morphine trials. To show a 40%
decrease (from 60% to 35%) of these side effects with a power of at least 80% (α =
0.05), a total sample size of 160 was needed. In all, 163 patients were enrolled.
Reduction of the behavioral pain score was chosen as a clinically significant
response in the alfentanil and ketamine trials. To calculate sample size in the
alfentanil trial, tracheal suction without pain relief was hypothesized to cause an
increase in behavioral pain score of 6 points. To show a 25% reduction in the pain
scores produced by either dose of alfentanil with a power of 90% (α = 0.05), a
sample size of 9 was needed; 10 patients were studied.
The sample size for the ketamine trial was calculated using the results of the
alfentanil trial. To show a reduction in pain score from a mean value of 5 to 2 (SD
3), corresponding to the observed scores after administering placebo and 10 µg/kg
alfentanil, with any dose of ketamine with a power of 80% (α = 0.05), 16 infants
should be enrolled.
In the fentanyl-morphine trial, comparison of the fentanyl and morphine baseline
data was performed with Student’s t-test or chi-squared test. Differences in
hormone concentrations were analyzed with Student’s t-test, and in case of skewed
distribution, a logarithmic transformation or the Mann-Whitney U-test was used.
The paired t-test was used for comparison of paired measurements from the same
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individual. The relationships between fentanyl and morphine clearances and
gestational age and birthweight were analyzed with Pearson’s correlation
coefficient. Comparison of the steady-state concentrations and fentanyl clearance in
infants delivered before or after 30 weeks of gestational age was performed with
Student’s t-test. The relation of morphine steady-state concentrations to responses
was analyzed with Student’s t-test (parametric data) or the Mann-Whitney U-test
(nonparametric data). In the alfentanil trial, the Wilcoxon signed-rank test and
Spearman's rank correlation coefficient were used, and in the ketamine trial the
paired Student’s t-test and the Wilcoxon signed-rank test were used. Analyses were
performed using the SPSS (version 8.0 for Windows; SPSS, Chicago, IL, USA)
software package.
7.7  Ethical considerations
The Ethics Committee of the hospital, and in the ketamine trial (V) also the Finnish
National Agency for Medicines, approved the study protocol in accordance with
current legislation. Written informed parental consent was obtained. Blood
sampling volumes were restricted because of the small size of the infants. If infants
were receiving blood transfusions on clinical indications, the sampling could be
completed according to protocol, since additional volume of packed red blood cells
was given to replace the blood volume sampled.
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8  RESULTS
8.1  Comparison of analgesic effects of fentanyl and morphine (I)
In the fentanyl and morphine groups, the pain score values during opioid infusion
prior to tracheal suction were similar [median 1 (IQR 0-3)], as were the score
changes in response to tracheal suction (I, Figure). The heart rate and mean arterial
blood pressure remained stable during drug infusions. Vasoactive agents were used
equally in both treatment groups.
Plasma catecholamine concentrations decreased significantly in both treatment
groups at 24 hours, but ß-endorphin decreased significantly only in the fentanyl
group (I, Table III) (Figure 1).
Decreased gastrointestinal motility occurred significantly less frequently in the
fentanyl group as compared with the morphine group (23% vs. 47%, p<0.01).
Urinary retention occurred in 56% of fentanyl-treated and 55% of morphine-treated
infants based on clinical evaluation, and in 36% and 37%, respectively, based on
ultrasound measurement. No adverse effects were observed in 28% of fentanyl-
treated and 32% of morphine-treated infants.
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Pain score did not correlate significantly with serum morphine steady-state values
during the second day of life; the steady-state morphine concentration was similar
in infants with and without effective pain relief (158 ± 60 and 148 ± 61 ng/ml,
respectively, III, Figure 3). Neither was there a correlation between metabolite
concentrations, M3G+morphine, or M6G+morphine concentrations and the ratio of
these concentrations to that of morphine. Infants with decreased gastrointestinal
motility had higher steady-state morphine concentrations (187 ± 82 ng/ml) than
infants with normal motility (128 ± 51 ng/ml) (III, Figure 3). Serum morphine
steady-state concentration correlated significantly with the postnatal age when
enteral feeding began (r=0.44, p<0.05).
8.4  Alfentanil as procedural pain relief (IV)
Attenuation of the pain score change was significant (p<0.05) in infants receiving
20 µg/kg alfentanil, but not in infants receiving 10 µg/kg alfentanil, when compared
with placebo (IV, Figure 3).
Serum alfentanil concentration increased with dose [median 21 (IQR 17 to 22)
ng/ml after 10 µg/kg and median 49 (IQR 40 to 50) ng/ml after 20 µg/kg]. Two
infants receiving placebo as their second dose still had detectable alfentanil
concentrations (11 ng/ml and 13 ng/ml) six hours after the alfentanil dose.
Tracheal suction was associated with an increased heart rate of 15 (IQR 13 to 16)
beats/min and an arterial blood pressure of 8 (IQR 6 to 14) mmHg in infants
receiving placebo. With 20 µg/kg alfentanil, a significant attenuation of the heart
rate change was noted; -7 (IQR -17 to -1) beats/min; p<0.05 compared with
placebo. Attenuation of the blood pressure change was not significant; 1 (IQR -6 to
6) mmHg (IV, Figure 1).
Plasma noradrenaline concentrations tended to decrease with increasing alfentanil
dose, but the change was not significant (IV, Figure 2). After 20 µg/kg of alfentanil,
the adrenaline concentration decreased (IV, Table 2). No significant changes were
found in ß-endorphin concentrations after any of the doses.
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9  DISCUSSION
Morphine and fentanyl in the doses administered seemed to provide efficient
analgesia; however, fentanyl may be superior for short-term postnatal use because
of the lesser risk for gastrointestinal dysmotility. The clearances of both morphine
and fentanyl were correlated with gestational age and birthweight. The dose of 20
µg/kg alfentanil relieved endotracheal suction-induced pain, but caused a high
incidence of rigidity, and thus should be used only in conjunction with a muscle
relaxant. Ketamine in the doses used had only a small or moderate analgesic effect,
and therefore seems to be a poor pretreatment for painful procedures.
9.1  Methodological considerations
The study was performed in only one NICU to achieve strict adherence to the
protocol and to standardize evaluation of pain and adverse effects. A randomized,
double-blind study design was used in fentanyl and morphine trials. Randomization
was performed in five blocks to minimize the influence of changing treatments
during the fairly long study period. A randomized, balanced, double-blind,
crossover study design was used in alfentanil and ketamine trials. The effect of
interindividual variation on the results in alfentanil and ketamine trials was
minimized because the subjects served as their own controls. Possible carry-over
effect in these trials was only partly prevented by randomization, since for clinical
reasons, wash-out periods between study phases were only 6 (alfentanil) and 12
(ketamine) hours. Due to the small sample size, a more detailed analysis of carry-
over effect and period effect were not possible. Moreover, the previous treatments
with morphine boluses in the alfentanil trial and fentanyl infusion in the ketamine
trial may have influenced results, although the time interval in both trials was at
least 12 hours.
The design of the randomized trial comparing morphine and fentanyl infusions
gave rise to speculation on the ethics of not including a placebo group (Kennedy
and Tyson 1999), which we found unacceptable because of the frequent need for
analgesia in these patients. One resolution to this problem might have been to
include a placebo group with an open-label use of analgesic bolus medication for
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clinical discomfort. However, in our setting, most placebo infants would have been
treated with boluses, and almost the entire control group would have been
contaminated and thus not informative. In addition, previous controlled trials have
shown that placebo-treated infants had increased plasma adrenaline (Quinn et al.
1993) and ß-endorphin (Ionides et al. 1994) concentrations and had suffered more
pain as judged by a pain scale (Jacqz-Aigrain et al. 1994) than morphine-, fentanyl-,
or midazolam-treated infants.
As a standard painful stimulus, endotracheal suction was used, which as part of
routine treatment is performed repeatedly. Endotracheal suction is associated with
acute cardiovascular changes, hypoxemia (Skov et al. 1992, Pokela 1994), release
of catecholamines (Greisen et al. 1985, Esuri et al. 1997), and atrial natriuretic
peptide (Esuri et al. 1997) in preterm neonates. While it is considered distressing
and unpleasant (Anand et al. 1999), how much of the associated response seen in
newborn infants is indeed caused by pain is unclear, since it may also cause vagal
reflex. Heel prick would have been a more reliable painful stimulus, but it could not
be used for ethical reasons, as sampling was performed from the arterial line.
The pain scale used in the present study was adopted from the NIPS, the most
suitable, valid pain-assessment tool at the time of beginning the study. NIPS as such
was not optimal for mechanically ventilated infants with oxygen saturation
monitoring and at least two peripheral lines restricting movement of arms and legs.
The scale used proved to be feasible and easy to manage, which is important when
repeated measurements are performed by several observers in a busy environment.
However, the scale is limited by its inclusion of only one physiological indicator,
and thus, should be used in combination with other physiological measures.
Recently, a study comparing three pain assessment measures (NIPS, SUN, and
Comfort scale) has been published (Blauer and Gerstmann 1998); NIPS proved to
be the easiest, and thus, the fastest to use (Blauer and Gerstmann 1998).
Evaluation of urinary retention, gastrointestinal motility, and rigidity were based on
previously defined criteria. Although subjective assessments, the blindness of the
observer and standardized evaluation made these measures reliable.
Because of blood volume restrictions, all parameters could not be measured in all
infants. In the subgroups with analyses performed, the patients did, however, not
differ from the entire study group regarding clinical characteristics, morbidity, or
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treatment. Sampling at time zero was not possible, sampling schedule was sparse,
and sampling after discontinuing the infusion was also not possible. Therefore, the
exact half-life could not be calculated. Urine collection was not performed because
of difficulties in obtaining complete collection from premature infants.
The plasma catecholamines and ß-endorphin were determined by HPLC method
and by radioimmunoassay, respectively. The concentrations of plasma fentanyl and
alfentanil were determined by radioimmunoassay, and ketamine, morphine, M3G,
and M6G by HPLC. The sensitivities of the laboratory methods for measuring drug
concentrations and stress indicators were sufficient, and the coefficients of variation
were satisfactory.
9.2  Analgesia for persistent pain
Comparison of fentanyl and morphine pharmacodynamics (I)
Fentanyl and morphine treatments in the doses used (fentanyl 10.5 µg/kg over a 1-
hour period followed by 1.5 µg/kg/h and morphine 140 µg/kg over a 1-hour period
followed by 20 µg/kg/h) provided equal analgesia, as judged by the pain score,
hemodynamic parameters, and hormonal stress response, while examining
adrenaline and noradrenaline concentrations. However, when taking ß-endorphin
into consideration, its reduction in plasma levels was significant only in the fentanyl
group, which ensued partly from a higher baseline ß-endorphin level in the fentanyl
group and small number of samples analyzed. Occurrence of the common opioid-
related side effect, decreased gastrointestinal motility, differed, favoring fentanyl.
Morphine and fentanyl dosages were based on previous pharmacokinetic and
pharmacodynamic results (Perlman and Volpe 1983, Roth et al. 1991, Chay et al.
1992, Quinn et al. 1993) indicating an equipotent analgesic effect. In line with these
studies, an equal analgesia was also achieved in the present study based on similar
pain score values and use of boluses.
Significant changes in mean blood pressure were neither associated with the
treatments, nor with response to tracheal suctioning. The decrease in heart rate was
slight and similar in both treatment groups during the infusion, and no response to
tracheal suction occurred. Lack of these physiological responses to the stimulus
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supports the view of sufficient analgesia. Vasopressors were given to most infants
prior to and during opioid infusion. Attention was also paid to correction of
possible hypovolemia before the beginning of infusion. Weaning from the opioid
infusion occurred gradually over 0.5 to 2 days depending on the duration of the
infusion, and no withdrawal symptoms were observed. Overall, both treatments
appeared clinically effective and safe when used over a short time period of 2 to 3
days.
Endocrine response can be used for determining pain and stress in newborn infants
with certain limitations. Release of stress hormones usually increases when an
infant is experiencing pain, but these increases may also be caused by underlying
disease, clinical condition, or handling. However, if no changes occur in stress
hormone levels, it is unlikely that an infant is experiencing pain.
Limited studies are available on the range of plasma catecholamine concentrations
in preterm infants (Ekblad et al. 1992). Term babies born vaginally express a
greater catecholamine surge than those born by cesarean section, with
concentrations falling rapidly by 2 hours and then declining more gradually until 24
hours (Faxelius et al. 1984). Increased plasma catecholamine levels have been
observed during surgery in newborn infants, adrenaline showing an immediate and
noradrenaline a delayed response (Anand et al. 1985, Anand et al. 1987, Anand et
al. 1990). Increases of both adrenaline and noradrenaline have been reported in
response to tracheal suctioning (Greisen et al. 1985). Evidence suggests that
adrenaline is a marker of acute pain and stress, while noradrenaline signifies
chronic pain and stress (Lagercrantz and Slotkin 1986). However, no difference
was found in catecholamine response between the two treatment groups, with a
reduction occurring at 24 hours of infusion. On the other hand, baseline
noradrenaline concentrations were increased compared with adrenaline
concentrations, which probably reflects the immaturity of the infants studied. The
relative proportion of adrenaline to noradrenaline increases with increasing maturity
due to a maturation of the enzyme (phenylethanolamine N-methyl transferase)
which converts noradrenaline to adrenaline (Quinn et al. 1992).
The usefulness of ß-endorphin as an indicator of pain has been debated. Previous
studies on newborn infants have shown a decrease in plasma ß-endorphin
concentration after opioid administration in mechanically ventilated neonates
(Ionides et al. 1994), and in response to tracheal intubation (Pokela and Koivisto
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1994). During cardiac surgery, the ß-endorphin increase occurred earlier than the
catecholamine response (Anand et al. 1990). In a study with preterm infants
suffering from respiratory difficulties, a significant increase in plasma ß-endorphin
concentration occurred from birth to the age of 2 hours, in comparison with infants
born after spontaneous delivery (Ruth et al. 1986). During acute neonatal
respiratory difficulties requiring mechanical ventilation, the plasma ß-endorphin
concentration remained increased for the duration of the illness (Hindmarsh et al.
1984). Overall, marked variability exists in plasma ß-endorphin values according to
previous findings (Ruth et al. 1986, Pokela and Koivisto 1994), with results of the
present study supporting this. The plasma ß-endorphin concentration decreased
only in the fentanyl group, and even though the baseline values in this group
seemed to be higher, the difference was significant. This may indicate lesser
distress in the infants treated with fentanyl.
The overall incidence of adverse effects was high. However, the exact relationship
between treatment and these adverse effects is unknown. Only one third of the
infants in both treatment groups had no side effects. Increased ventilatory
requirements, which have been reported both with morphine (Quinn et al. 1992)
and fentanyl (Orsini et al. 1996), were not noticed. Neither did we observe
withdrawal symptoms, which have been reported with prolonged use of opioids and
especially with fentanyl doses exceeding 1.6 mg/kg or infusion lasting more than 5
days (Arnold et al. 1990). The duration of opioid infusion in the present study was
about 2-2.5 days.
Pharmacokinetic studies (II,III)
The total body clearances of both fentanyl and morphine correlated with gestational
age and birthweight in the immediate postnatal period. However, their contribution
to variance (r2) was low or moderate (21 to 36%), indicating that other factors, such
as variations in volume of distribution with gestational age and disease state, play a
larger role in determining fentanyl and morphine levels.
In the fentanyl subgroup, patients were somewhat heterogenous with regard to
diagnoses, but postnatal age was similar and known inhibitors of the CYP3A4 were
not administered. Increased fentanyl levels were assumed to provide better
analgesia since the pain score value correlated inversely with the fentanyl steady-
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state concentration. Increased fentanyl levels also seemed to postpone beginning of
enteral feeding. Again, however, the contribution to variance (r2) was low or
moderate (16 to 32%). Higher steady-state concentrations were observed in very
premature infants than in those delivered after 30 gestational weeks. This seems to
reflect maturation of drug metabolism after 30 gestational weeks, although large
interindividual variations occur. The steady state was reached between 24 and 48
hours, consistent with a fentanyl half-life of about 7-15 hours in this population. In
a previous study of 12 infants of postnatal age less than 4 days, a half-life of 6 hours
was reported (Koehntop et al. 1986).
Elimination of fentanyl depends both on liver blood flow and on activity of
CYP3A4 enzyme (Scholz et al. 1996). Conditions which cause increased
abdominal pressure, such as necrotizing enterocolitis, have been associated with
decreased fentanyl clearance (Koehntop et al. 1986). In the present study, four of
the five infants with necrotizing enterocolitis had decreased fentanyl clearance.
Immaturity of the hepatic enzyme system and the balance between fetal
predominant CYP3A7 and the major adult form CYP3A4 (Hakkola et al. 1998)
may explain some of the age-related differences in fentanyl metabolism. A general
increase occurs in the drug metabolism during the first weeks of life probably
because of redistribution of hepatic blood flow and exposure of the neonatal liver to
inducing agents (Morselli 1976).
Overall, the clearance of fentanyl was lowest in the most premature infants,
indicating that elimination is slowed and half-life prolonged with immaturity. These
results are in line with the few previous studies performed in the immediate
postnatal period. Mean clearances have been reported at 7.4 ml/min/kg in 5 infants
during the first postnatal week and 23.6 ml/min/kg in 5 infants during the second
postnatal week, when fentanyl was given prior to surgery (Gauntlett et al. 1988).
The most remarkable increase in fentanyl clearance occurred by two weeks of age
(Gauntlett et al. 1988), with these authors concluding that approximately 30% of
the variability could be explained by postnatal age (r2=0.31). Two infants who had
undergone trough abdominal surgery did not seem to eliminate the drug at all. An
experimental study on newborn lambs showed a similar increase in clearance
during the first two weeks of age, with more than half of the variability being
explained by age (r2=0.56) (Gauntlett et al. 1988). A mean clearance of 17.9
ml/min/kg and an elimination half-life of 5.3 hours were observed in 14 infants
undergoing major surgery during the early postnatal period (Koehntop et al. 1986).
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A wide range of fentanyl clearance (2.0 to 85.0 ml/min/kg) was observed in infants
receiving fentanyl for sedation and analgesia during intensive care because of
severe respiratory distress syndrome, cardiac disorders, or cerebral disorders (Roth
et al. 1991). This variability might be due to differences in postnatal age, underlying
disease, or concomitant treatment with phenobarbital, an inducer of CYP3A4
enzyme. However, in our study, fentanyl clearance in five infants treated
concomitantly with phenobarbital, ranging from 8.1 to 13.9 ml/min/kg, was similar
to that in the rest of the study group.
In the morphine subgroup, both metabolites M3G and M6G were detectable fairly
early after the beginning of morphine infusion. This indicates that even premature
infants are capable of metabolizing morphine. In fact, the ratio of both metabolites
to morphine increased with increasing gestational age, indicating enhanced
glucuronidation with maturity. Serum morphine concentration seemed to reach
steady state between 24 and 48 hours, and even earlier in a few infants. Thus, the
estimated half-life of morphine is about 7-15 hours. In a recent study performed
during a postnatal age period of less than 3 days, the elimination half-life of
morphine was estimated at 5-21 hours in 26 preterm infants (Scott et al. 1999).
M3G and M6G metabolites did not reach steady state during the 60-hour study
period, so their clearances could not be calculated. Neither concentration of
morphine nor of either metabolite was correlated with analgesic effect, but high
steady-state morphine concentration was associated with decreased gastrointestinal
motility.
Data on morphine pharmacokinetics and pharmacodynamics in preterm infants in
the immediate postnatal period are limited (Kart et al. 1997). In the present study,
the clearance of morphine ranged from 0.8 to 6.5 ml/min/kg, which is in line with
previous studies on subjects of the same age range. The mean clearance of 2.3
ml/min/kg was reported for the most immature infants delivered before the
gestational age of 28 weeks (Scott et al. 1999). For infants delivered at the
gestational age of 28 to 31 weeks, the mean clearance varied between 3.2 and 3.5
ml/min/kg (Barret et al. 1991, Scott et al. 1999), whereas for infants delivered at
gestational age of 32 to 35 weeks clearance was 1.7 ml/min/kg (Chay et al. 1992).
In term infants, clearance has varied between 2 and 6 ml/kg/min (Lynn and Slattery
1987, Chay et al. 1992, McRorie et al. 1992), which is in agreement with results for
the few term infants included in our study. However, despite the similar clearances
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in previous studies, only the recent study by Scott et al. (1999) has demonstrated
the same relationship between gestational age and clearance as the present study.
The concentration of morphine providing analgesia varies widely in infants.
Consistent with findings of Scott et al. (1999) no correlation between analgesic
effect and morphine levels was found. However, with our treatment regimen, mean
concentrations of 105 ng/ml at 2 hours and 125 ng/ml from 12 hours onward were
reached, levels which have been considered sufficient for sedation in newborn
infants (Chay et al. 1992). In Chay’s study, morphine concentrations above 300
ng/ml were associated with adverse effects including bradycardia, carbon dioxide
retention, and urinary retention. In the present study an even lower concentration of
187 ng/ml was associated with decreased gastrointestinal motility. No association
between morphine or metabolite concentrations and other adverse effects could be
shown. However, overall incidence of adverse effects was high, at 68% in all
(n=80) morphine-treated infants.
Morphine metabolism is diminished during the neonatal period (Pacifici et al. 1982,
Choonara et al. 1989). M3G, an antagonist of morphine analgesia (Smith et al.
1990), is the predominant metabolite in the neonatal period, whereas M6G, a potent
analgesic and respiratory depressant (Osborne et al. 1992), is detected at much
lower concentrations than in full-term neonates and children (Choonara et al. 1992).
In this study, the M3G concentration exceeded that of morphine at 24 hours, while
the M6G concentration reached about one third of morphine concentration at 48
hours. Decreased formation of M6G may explain the higher levels of morphine
needed for sufficient analgesia, even though no correlation between analgesic effect
and M6G or the sum of morphine and M6G was found. The increased
concentrations of M3G may in part explain the decreased sensitivity to the
respiratory depressant effect of morphine (Hartley et al. 1994).
9.3  Procedural pain management (IV,V)
When performing tracheal suction without analgesia, an increase in both blood
pressure and heart rate was seen, which concurs with previous studies (Perlman and
Volpe 1983, Skov et al. 1992). A increase in blood pressure and heart rate also
occurred in response to tracheal suction after 10 µg/kg alfentanil and all doses of
ketamine. Only after 20 µg/kg alfentanil was a significant attenuation in heart rate
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found. These hemodynamic changes are probably related to vagal reflex and pain
caused by tracheal suction. However, an effect of ketamine on release of
catecholamines from endogenous sources (Takki et al. 1972) cannot be excluded.
The changes in plasma catecholamine concentrations were somewhat confounding
(IV, Table 2; V, Table 4), although increased catecholamine levels have previosly
been reported during suctioning (Greisen et al. 1985). Several samples in the
alfentanil trial had concentrations below the detection limit, possibly relating to the
immaturity of the infants studied. Overall, catecholamine concentrations showed
great variability, and only noradrenaline tended to decrease with increasing
alfentanil dose.
The behavioral pain score increased in response to tracheal suction after placebo. A
similar increase was also seen with 10 µg/kg alfentanil and all doses of ketamine.
The dose of 20 µg/kg alfentanil abolished the pain score change and 1 mg/kg
ketamine attenuated it.
Alfentanil and ketamine concentrations increased with the increasing dose. After 20
µg/kg alfentanil, the concentration (40-50 ng/ml) was comparable with the
analgesic concentration recommended for sedation in older age groups (35-50
ng/ml) (Marlow et al. 1990). With the ketamine doses of 1 and 2 mg/kg the
concentrations (189 ng/ml and 379 ng/ml, respectively) corresponded with those
reported for sufficient analgesia (Grant et al. 1981). Detectable, but minor
concentrations were measured in some infants six hours after the previous alfentanil
dose and twelve hours after the previous ketamine dose.
As an adverse effect, severe muscle rigidity occurred in more than half of the
infants treated with the 20 µg/kg dose of alfentanil. Since rigidity was previously
reported with 9 µg/kg alfentanil (Pokela et al. 1992), attention was paid to slow
administration of the solution. Because psychic emergence phenomenon is a known
adverse effect of ketamine in children and adults (White et al. 1982), the poor dose-
effect relationship was speculated to be related to discomfort caused by the highest
ketamine dose. Thus, in infants in whom repeated tracheal suctions are judged to be
clearly painful, a continuous infusion might be more appropriate than a
pretreatment.
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10  CONCLUSIONS
The main conclusions of this study aimed at designing pain relief applicable in
clinical practice to persistent pain and procedural pain are:
1. When comparing continuous infusions of fentanyl (10.5 µg/kg over a 1-hour
period followed by 1.5 µg/kg/h) and morphine (140 µg/kg over a 1-hour period
followed by 20 µg/kg/h), fentanyl-treated infants had a lower incidence of
decreased gastrointestinal motility. Thus, fentanyl may offer a superior
treatment, especially for premature infants with a high risk for gastrointestinal
dysmotility.
2. Substantial interindividual variability was present in fentanyl and morphine
clearances in newborn infants. However, the clearances correlated with both
gestational age and birthweight. The analgesic effect correlated with fentanyl
but not morphine steady-state concentrations. Enteral feeding was postponed
with high fentanyl concentrations, and decreased gastrointestinal motility was
associated with high morphine concentrations.
3. Dosages of fentanyl and morphine should not only be based on careful
monitoring of individual responses, but also on the degree of newborn
immaturity. A loading dose followed by continuous infusion appeared clinically
safe and effective.
4. Mechanically ventilated newborn infants experience endotracheal suction as an
unpleasant and painful procedure. Alfentanil at a dose of 20 µg/kg relieved pain,
but caused rigidity as an adverse effect, thus being an inappropriate option
without concomitant muscle relaxant. With ketamine, hemodynamic stability
was maintained. However, the doses of 0.5, 1, and 2 mg/kg had only small or
moderate analgesic effect, and thus, ketamine alone appears to be a poor
pretreatment for endotracheal suction-induced pain.
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